Markets:

Overview

News

Currencies

International

Treasuries

Intellia Therapeutics, Inc. - Common Stock (NQ:NTLA)

8.265 -0.215 (-2.53%)

Streaming Delayed Price Updated: 11:09 AM EST, Nov 18, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Intellia Therapeutics, Inc. - Common Stock

< Previous 1 2

...

14 15 16 17 18 19 20 21 Next >

The 3 Leaders of the Gene Editing Revolution ↗

July 08, 2022

There's a wide field of gene editing stocks, but if you're looking for the best opportunities, there are a few likely winners to watch.

Via InvestorPlace

7 Moonshot Investments Upending a $10 Trillion Industry ↗

July 08, 2022

Gene editing is expensive at an estimated $5 billion per drug, but it could change the world in the very near future.

Via InvestorPlace

Do You Have Biotech FOMO? It Might Be Time To Pay Attention To These Names ↗

July 06, 2022

Biotech stocks continued going gangbusters Wednesday. Here's why, experts say.

Via Investor's Business Daily

Do You Have Biotech FOMO? Why Cogent, Arvinas And Others Are Flying ↗

July 06, 2022

Biotech stocks continued going gangbusters Wednesday. Here's why, experts say.

Via Investor's Business Daily

Intellia's Gene-Editing Candidate Shows Durability In ATTR Amyloidosis ↗

June 24, 2022

Via Benzinga

BMO Initiates Coverage On This Gene Editing Spearhead ↗

June 17, 2022

Via Benzinga

4 Analysts Have This to Say About Intellia Therapeutics ↗

April 28, 2022

Analysts have provided the following ratings for Intellia Therapeutics (NASDAQ:NTLA) within the last quarter:

Via Benzinga

Analyst Ratings for Intellia Therapeutics ↗

June 16, 2022

Over the past 3 months, 7 analysts have published their opinion on Intellia Therapeutics (NASDAQ:NTLA) stock. These analysts are typically employed by large Wall Street banks and tasked with...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 16, 2022 ↗

June 16, 2022

Upgrades

Via Benzinga

Analyst Ratings for Intellia Therapeutics ↗

May 24, 2022

Over the past 3 months, 8 analysts have published their opinion on Intellia Therapeutics (NASDAQ:NTLA) stock. These analysts are typically employed by large Wall Street banks and tasked with...

Via Benzinga

10 Biggest Price Target Changes For Monday ↗

May 09, 2022

Morgan Stanley cut Guardant Health, Inc. (NASDAQ: GH) price target from $120 to $85. Guardant Health shares rose 4.3% to $40.99 in pre-market trading.

Via Benzinga

The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study ↗

May 05, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Earnings Preview For Intellia Therapeutics ↗

May 04, 2022

Intellia Therapeutics (NASDAQ:NTLA) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that...

Via Benzinga

How To Attend Intellia Therapeutics Q1 2022 Earnings Conference Call ↗

May 02, 2022

Intellia Therapeutics (NASDAQ:NTLA) will host a conference call at 08:00 AM ET on May 5, 2022, to discuss Q1 2022 earnings results.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For April 28, 2022 ↗

April 28, 2022

Via Benzinga

Stocks That Hit 52-Week Lows On Thursday ↗

April 21, 2022

On Thursday, 236 companies hit new 52-week lows.

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday ↗

April 20, 2022

On Wednesday, 160 companies hit new 52-week lows. Areas of Significance In Today's 52-Week Lows: Walt Disney (NYSE:DIS) was the largest firm by market cap to set a new...

Via Benzinga

Good Entry Point for Biotech Stocks ↗

April 04, 2022

Life science and biotech stocks had a good week with the most well-known ETFs up 3-4% for the week and off recent bottoms.

Via Talk Markets

FDA Recommends At Least 15 years Of Follow-Up For Genome Editing Product Trials ↗

March 15, 2022

The FDA has outlined new draft guidance on what should be submitted in a clinical trial application and potentially concerning safety issues to track the genome editing products.

Via Benzinga

Here's How Much $100 Invested In Intellia Therapeutics 5 Years Ago Would Be Worth Today ↗

March 15, 2022

Intellia Therapeutics (NASDAQ:NTLA) has outperformed the market over the past 5 years by 19.59% on an annualized basis. Buying $100 In NTLA: 5 years ago, an investor could have...

Via Benzinga

Intellia's CRISPR-Engineered Cell Therapy Receives FDA Orphan Drug Tag For Bone Marrow Cancer ↗

March 10, 2022

Intellia Therapeutics Inc's (NASDAQ: NTLA) CRISPR-powered T cell therapy has received an FDA orphan drug designation. The autologous T cell receptor therapy, dubbed...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For March 7, 2022 ↗

March 07, 2022

Upgrades According to Brookline Capital, the prior rating for Intellia Therapeutics Inc (NASDAQ:NTLA) was changed from Hold to Buy. In the fourth quarter, Intellia Therapeutics...

Via Benzinga

63 Biggest Movers From Yesterday ↗

March 04, 2022

Gainers Indonesia Energy Corporation Limited (NASDAQ: INDO) shares climbed 39.3% to close at $20.20 on Thursday after jumping around 35% on Wednesday. DBV Technologies S.A. (...

Via Benzinga

44 Stocks Moving In Tuesday's Mid-Day Session ↗

March 01, 2022

Gainers Avenue Therapeutics, Inc. (NASDAQ: ATXI) climbed 193% to $0.9962 after jumping 36% on Monday. GBS Inc. (NASDAQ: GBS) rose 73.3% to $0.7971 after declining around 9% on...

Via Benzinga

80 Biggest Movers From Yesterday ↗

March 02, 2022

Gainers Avenue Therapeutics, Inc. (NASDAQ: ATXI) jumped 78.5% to close at $0.6066 on Tuesday after jumping 36% on Monday. CTI BioPharma Corp. (NASDAQ: CTIC) surged 63...

Via Benzinga

Analyst Ratings For Intellia Therapeutics ↗

March 01, 2022

Over the past 3 months, 4 analysts have published their opinion on Intellia Therapeutics (NASDAQ:NTLA) stock. These analysts are typically employed by large Wall Street banks and...

Via Benzinga

The Daily Biotech Pulse: Legend Biotech, CTI Biopharma Receive FDA Approvals, AbbVie Announces Delay In Skyrizi Review, Editas Gains On CRISPR Patent Resolution ↗

March 01, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Editas Gains On Resolution Of CRISPR Gene Editing Patent Case Editas Medicine...

Via Benzinga

Intellia Shares Updated Data On Gene Editing Durability In Rare Disease ↗

March 01, 2022

Eight months after delivering promising biomarker data from one of the first CRISPR trials, Intellia Therapeutics Inc (NASDAQ: NTLA) presented additional data...

Via Benzinga

Intellia Therapeutics Crashes As Patent Decision Clouds CRISPR Gene-Editing Test ↗

February 28, 2022

Intellia Therapeutics said its gene-editing drug lowered levels of a troublesome protein.

Via Investor's Business Daily

12 Health Care Stocks Moving In Monday's After-Market Session ↗

February 28, 2022

Gainers GBS (NASDAQ:GBS) stock rose 10.9% ...

Via Benzinga

< Previous 1 2

...

14 15 16 17 18 19 20 21 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Intellia Therapeutics, Inc. - Common Stock (NQ:NTLA)

All News about Intellia Therapeutics, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today